Amgen unveils five-year survival data for Blincyto
Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note
Read More
Tag: Blincyto
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
NICE has requested further evidence on Amgen’s Blincyto for the treatment of adults with acute lymphoblastic leukaemia.
Read More
EU expands use of Amgen’s Blincyto
European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.
Read More
Amgen’s Blincyto gets full EU approval for rare leukaemia
European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to affect around 900 patients a year in the region.
Read More
Amgen’s Blincyto wins full US approval
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Read More
NICE nod for Amgen’s rare leukaemia drug
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE.
Read More
FDA OKs paediatric use of Amgen’s Blincyto
US regulators have issued an accelerated approval for use of Amgen’s immunotherapy Blincyto to treat paediatric patients with a rare form of leukaemia.
Read More
Four new medicines OK’d for use by NHS Scotland
Cost regulators have approved the use of four new medicines for use by NHS Scotland, including a new option for Parkinson’s disease and asthma, but rejected Sanofi-Genzyme’s Jevtana for prostate cancer and Amgen’s Repatha for high cholesterol.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
